Supernus Pharmaceuticals Inc

詳細情報 Supernus Pharmaceuticals Inc 企業名

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

企業情報

企業コードSUPN

会社名Supernus Pharmaceuticals Inc

上場日Dec 28, 2010

最高経営責任者「CEO」Mr. Jack A. Khattar

従業員数674

証券種類Ordinary Share

決算期末Dec 28

本社所在地9715 Key West Avenue

都市ROCKVILLE

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号20850

電話番号13018382500

ウェブサイトhttps://www.supernus.com

企業コードSUPN

上場日Dec 28, 2010

最高経営責任者「CEO」Mr. Jack A. Khattar

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.01M

--

Mr. Frederick M. Hudson, CPA

Independent Director

53.76K

--

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs

15.15K

+4.64%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

12.70K

+7.63%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

12.68K

+7.65%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

9.63K

+8.32%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Ms. Bethany L. Sensenig

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.01M

--

Mr. Frederick M. Hudson, CPA

Independent Director

53.76K

--

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs

15.15K

+4.64%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

12.70K

+7.63%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Net product sales-Qelbree

64.75M

43.21%

Net product sales - GOCOVRI

30.69M

20.48%

Net product sales-APOKYN

14.98M

10.00%

Net product sales- Trokendi XR

12.80M

8.54%

Net product sales- Oxtellar XR

10.20M

6.81%

Other

16.41M

10.96%

地域別USD

会社名

収益

比率

United States

149.82M

100.00%

事業別

地域別

事業別USD

会社名

収益

比率

Net product sales-Qelbree

64.75M

43.21%

Net product sales - GOCOVRI

30.69M

20.48%

Net product sales-APOKYN

14.98M

10.00%

Net product sales- Trokendi XR

12.80M

8.54%

Net product sales- Oxtellar XR

10.20M

6.81%

Other

16.41M

10.96%

株主

更新時刻: Thu, May 8

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.65%

The Vanguard Group, Inc.

10.99%

Armistice Capital LLC

9.28%

Dimensional Fund Advisors, L.P.

5.19%

Macquarie Investment Management

4.82%

Other

55.07%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.65%

The Vanguard Group, Inc.

10.99%

Armistice Capital LLC

9.28%

Dimensional Fund Advisors, L.P.

5.19%

Macquarie Investment Management

4.82%

Other

55.07%

種類

株主統計

比率

Investment Advisor

56.83%

Investment Advisor/Hedge Fund

30.46%

Hedge Fund

15.36%

Individual Investor

4.11%

Research Firm

2.96%

Pension Fund

1.70%

Venture Capital

0.93%

Bank and Trust

0.70%

Sovereign Wealth Fund

0.27%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

563

63.74M

113.85%

-2.63M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

2023Q2

534

61.11M

111.93%

-1.60M

2023Q1

539

59.34M

108.94%

-3.56M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

8.20M

14.65%

-297.23K

-3.50%

Mar 31, 2025

The Vanguard Group, Inc.

6.15M

10.99%

+13.13K

+0.21%

Mar 31, 2025

Armistice Capital LLC

5.20M

9.28%

+360.00K

+7.44%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.90M

5.19%

+25.18K

+0.87%

Mar 31, 2025

Macquarie Investment Management

2.70M

4.82%

+70.76K

+2.69%

Mar 31, 2025

State Street Global Advisors (US)

2.15M

3.83%

-42.85K

-1.96%

Mar 31, 2025

Khattar (Jack A)

2.01M

3.6%

--

Apr 22, 2025

Renaissance Technologies LLC

1.59M

2.83%

-13.00K

-0.81%

Mar 31, 2025

Stephens Investment Management Group, LLC

1.74M

3.1%

-13.59K

-0.78%

Mar 31, 2025

Loomis, Sayles & Company, L.P.

1.44M

2.57%

-26.38K

-1.80%

Mar 31, 2025

詳細を見る

36.329USD

Supernus Pharmaceuticals Inc

36.329

概要

企業名

金融